Intravesical bacillus Calmette-Guerin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder - 15 years outcome

By Baniel J.   Grauss D.   Engelstein D.   Sella A.  

Urology, Vol. 52, Iss. 5, 1998-11 ,pp. : 785-789

Elsevier

Access to resources Recommend Favorite

Pretreatment P53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with bacillus calmette-guerin (BCG)

By Saint F.   Le Frere Belda M.A.   Quitela R.   Gil Diez De Medina S.   Hoznek A.   Patard J.J.   Bellot J.   Popov Z.   Zafrani E.S.   Abbou C.C.   Chopin D.  

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 86-86

Elsevier

Access to resources Recommend Favorite

Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guerin therapy

By Peyromaure M.   Weibing S.   Sebe P.   Verpillat P.   Toublanc M.   Dauge M.-C.   Boccon-Gibod L.   Ravery V.  

Urology, Vol. 59, Iss. 3, 2002-03 ,pp. : 409-413

Elsevier

Access to resources Recommend Favorite

In situ transitional cell carcinoma involvement of prostatic urethra: Bacillus Calmette-Guerin therapy without previous transurethral resection of the prostate

By Palou J.   Xavier B.   Laguna P.   Montlleo M.   Vicente J.  

Urology, Vol. 47, Iss. 4, 1996-04 ,pp. : 482-484

Elsevier

Access to resources Recommend Favorite

Additional bacillus Calmette-Guerin therapy for recurrent transitional cell carcinoma after an initial complete response

By Bui T.T.   Schellhammer P.F.  

Urology, Vol. 49, Iss. 5, 1997-05 ,pp. : 687-691

Elsevier

Access to resources Recommend Favorite